The latest price target for Sana Biotechnology (NASDAQ:SANA) was reported by HC Wainwright & Co. on November 27, 2024. The analyst firm set a price target for $8.00 expecting SANA to rise to within 12 months (a possible 384.85% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Sana Biotechnology (NASDAQ:SANA) was provided by HC Wainwright & Co., and Sana Biotechnology reiterated their buy rating.

The last upgrade for Sana Biotechnology Inc happened on January 16, 2024 when HC Wainwright & Co. raised their price target to $12. HC Wainwright & Co. previously had a neutral for Sana Biotechnology Inc.

The last downgrade for Sana Biotechnology Inc happened on November 5, 2024 when JMP Securities changed their price target from N/A to N/A for Sana Biotechnology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sana Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sana Biotechnology was filed on November 27, 2024 so you should expect the next rating to be made available sometime around November 27, 2025.

While ratings are subjective and will change, the latest Sana Biotechnology (SANA) rating was a reiterated with a price target of $8.00 to $8.00. The current price Sana Biotechnology (SANA) is trading at is $1.65, which is out of the analyst’s predicted range.